Triple positive (ER+PR+/HER-2+) breast carcinomas occur at a younger age than all other ER/PR/HER-2 breast cancer phenotypes

被引：0
|
作者：
Neven, P. [1 ,2 ]
Bempt, I. Vanden [3 ]
Van Calster, B. [4 ]
Hendrickx, W. [5 ]
De Cock, J. [5 ]
Cheng, J. [4 ]
Timmerman, D. [2 ]
Paridaens, R. [1 ,6 ]
Christiaens, M. R. [1 ,7 ]
Drijkoningen, M. [1 ,3 ]
机构：
[1] UZ Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium
[2] UZ Leuven, Dept Obstet & Gynecol, Leuven, Belgium
[3] UZ Leuven, Dept Histopathol, Leuven, Belgium
[4] Katholieke Univ Leuven, ESAT KU Leuven, Leuven, Belgium
[5] UZ Leuven, Datamanagement MBC, Leuven, Belgium
[6] UZ Leuven, Dept Med Oncol, Leuven, Belgium
[7] UZ Leuven, Dept Surg, Leuven, Belgium
来源：
BREAST | 2007年 / 16卷
关键词：
D O I：
10.1016/S0960-9776(07)70119-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [1] Clinical and biologic features of ER-PR-HER-2-breast cancer compared to estrogen or HER-2 driven phenotypes.
    Arpino, G
    Weiss, H
    Elledge, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 863S - 863S
  • [2] Immunophenotype of estrogen receptor (ER), progesterone receptor (PR) and HER-2 negative breast carcinomas
    Vladika, Natalia
    Anestakis, Doxakis
    Xirou, Persefoni
    Chatzinikolaou, Fotios
    Gianna, Kalliopi
    Patakiouta, Frideriki
    VIRCHOWS ARCHIV, 2007, 451 (02) : 200 - 200
  • [3] MEDULLARY BREAST CANCER HETEROGENEITY: AN IMMUNOHISTOCHEMICAL ANALYSIS OF ER, PR AND HER-2 EXPRESSION
    Juretic, A.
    Matkovic, B.
    Separovic, V.
    Novosel, I.
    Separovic, R.
    Gamulin, M.
    Kruslin, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 58 - 58
  • [4] Breast Cancer Subtypes Identified by the ER, PR and HER-2 Status in Thai Women
    Chuthapisith, Suebwong
    Permsapaya, Watthanasak
    Warnnissorn, Malee
    Akewanlop, Charuwan
    Sirivatanauksorn, Vorapan
    Osoth, Poramaporn Prasarttong
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (02) : 459 - 462
  • [5] A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER+, PR+, ER+PR+ and HER2- expression in women
    Zhang, Mei
    Guo, Ling-Ling
    Cheng, Zhongqin
    Liu, Reng-Yun
    Lu, Yufeng
    Qian, Qian
    Lei, Zhe
    Zhang, Hong-Tao
    ONCOLOGY LETTERS, 2011, 2 (04) : 653 - 658
  • [6] Correlation of ER/PR status and HER-2 status in invasive breast carcinoma
    Bloom, K. J.
    Kyshtooboyeva, A.
    Chen, S.
    Hii, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S248 - S248
  • [7] EVALUATION OF BRCA 1-2 GENE MUTATIONS IN PATIENTS WITH TRIPLE NEGATIVE AND ER(-), PR(-), HER-2(+) BREAST CANCER
    Uzal, M. C.
    Sener, S.
    Ozen, A.
    Cakina, S.
    Sipahi, T.
    Cosar, R.
    Gulyasar, T.
    Karagol, H.
    Yalcin, O.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S299 - S299
  • [8] Age, race/ethnicity, and the ER/PR/HER2 subtypes in breast cancer.
    Parise, Carol
    Caggiano, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Personalizing Breast Cancer Staging by the Inclusion of ER, PR, and HER2
    Bagaria, Sanjay P.
    Ray, Partha S.
    Sim, Myung-Shin
    Ye, Xing
    Shamonki, Jaime M.
    Cui, Xiaojiang
    Giuliano, Armando E.
    JAMA SURGERY, 2014, 149 (02) : 125 - 129
  • [10] QuantiGene 2.0 Assay for ER, PR and HER2 RNA Levels Is a Useful Adjunctive for the Evaluation of ER, PR and HER2 in Breast Cancer
    Lee, A.
    Chae, B. J.
    Song, B. J.
    Jung, S. S.
    Yim, H. W.
    CANCER RESEARCH, 2009, 69 (24) : 758S - 758S
12345